Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes

被引:0
作者
Araz Rawshani
Darren K. McGuire
Elmir Omerovic
Naveed Sattar
John J. V. McMurray
Ulf Smith
Bjorn Redfors
Lennart Bergfeldt
Bjorn Eliasson
Jan Borén
Deepak L. Bhatt
Goran Bergstrom
Aidin Rawshani
机构
[1] University of Gothenburg,Department of Molecular and Clinical Medicine, Institute of Medicine
[2] University of Gothenburg,Wallenberg Laboratory for Cardiovascular and Metabolic Research, Institute of Medicine
[3] University of Texas Southwestern Medical Center,Department of Internal Medicine
[4] and Parkland Health and Hospital System,Institute of Cardiovascular and Medical Sciences
[5] British Heart Foundation Glasgow Cardiovascular Research Centre,The Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine
[6] Sahlgrenska University Hospital,Brigham and Women’s Hospital Heart and Vascular Center
[7] Harvard Medical School,undefined
来源
Scientific Reports | / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The association between type 2 diabetes (T2D) and the development of cardiac arrhythmias and conduction disturbances has not been extensively studied. Arrhythmia was defined as atrial fibrillation and flutter (AF/AFl), ventricular tachycardia (VT) and ventricular fibrillation (VF), and conduction abnormality as sinus node disease (SND), atrioventricular (AV) block or pacemaker implantation, and intraventricular conduction blocks (IVCB). Incidence rates and Cox regression were used to compare outcomes, and to assess optimal levels for cardiometabolic risk factors and risk associated with multifactorial risk factor control (i.e., HbA1c, LDL-C, systolic blood pressure (SBP), BMI and eGFR), between patients with versus without T2D. The analyses included data from 617,000 patients with T2D and 2,303,391 matched controls. Patients with diabetes and the general population demonstrated a gradual increase in rates for cardiac conduction abnormalities and virtually all age-groups for AF/AFI showed increased incidence during follow-up. For patients with versus without T2D, risks for cardiac arrhythmias were higher, including for AF/AFl (HR 1.17, 95% CI 1.16–1.18), the composite of SND, AV-block or pacemaker implantation (HR 1.40, 95% CI 1.37–1.43), IVCB (HR 1.23, 95% CI 1.18–1.28) and VT/VF (HR 1.08, 95% CI 1.04–1.13). For patients with T2D who had selected cardiometabolic risk factors within target ranges, compared with controls, risk of arrythmia and conduction abnormalities for T2D vs not were: AF/AFl (HR 1.09, 95% CI 1.05–1.14), the composite of SND, AV-block or pacemaker implantation (HR 1.06, 95% CI 0.94–1.18), IVCB (HR 0.80, 95% CI 0.60–0.98), and for VT/VF (HR 0.97, 95% CI 0.80–1.17). Cox models showed a linear risk increase for SBP and BMI, while eGFR showed a U-shaped association. Individuals with T2D had a higher risk of arrhythmias and conduction abnormalities than controls, but excess risk associated with T2D was virtually not evident among patients with T2D with all risk factors within target range. BMI, SBP and eGFR displayed significant associations with outcomes among patients with T2D.
引用
收藏
相关论文
共 121 条
[1]  
Rawshani A(2017)Mortality and cardiovascular disease in type 1 and type 2 diabetes N. Engl. J. Med. 376 1407-1418
[2]  
Rawshani A(2016)Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study Eur. J. Prev. Cardiol. 23 621-627
[3]  
Franzen S(1998)Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates Am. J. Cardiol. 82 2N-9N
[4]  
Eliasson B(2018)Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 379 633-644
[5]  
Svensson AM(2018)Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 379 633-644
[6]  
Miftaraj M(2010)Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study Am. Heart J. 159 850-856
[7]  
Pallisgaard JL(2013)Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial JAMA 310 2050-2060
[8]  
Schjerning AM(2014)Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study J. Am. Coll. Cardiol. 64 2222-2231
[9]  
Lindhardt TB(2015)Long-Term effect of goal-directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY) J. Am. Coll. Cardiol. 65 2159-2169
[10]  
Procida K(2020)Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial Circulation 141 1227-1234